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RESUMO
Introdução: Na consulta de Hematologia-Obstetrícia do Centro Hospitalar São João EPE, as grávidas com trombofilias, episódios 
trombóticos anteriores e/ou história familiar de trombofilia são avaliadas e medicadas, recorrendo a uma escala de estratificação de 
risco (EER Hema-Obs).
Objectivos: Pretende-se, com este trabalho, avaliar a eficácia desta escala de estratificação de risco, comparando-a com uma escala 
semelhante, desenvolvida e publicada por Sarig (escala de estratificação de risco Sarig). 
Material e Métodos: Procedeu-se às seguintes comparações: distribuição, por grupos de risco, obtida pela aplicação das duas es-
calas, em simultâneo, a 250 grávidas seguidas, na consulta do Centro Hospitalar São João EPE; sensibilidade e especificidade para 
cada uma das escalas (teste DeLong aplicado às curvas Receiver Operating Characteristic); desfechos nas gestações seguidas no 
Centro Hospitalar São João EPE e pelo grupo de Sarig no Rambam Health Care Campus (Israel).
Resultados: A estratificação de risco nas 250 grávidas foi: a) com a escala de estratificação de risco Hema-Obs - Risco Materno 
(29%), Alto Risco Materno-Fetal (47%), Muito Alto Risco Materno-Fetal (24%); b) com a escala de estratificação de risco Sarig - Baixo 
(24%), Intermédio (53%), Alto (16%), Muito Alto (7%). Aplicando as curvas Receiver Operating Characteristic a ambas as escalas, 
resultam áreas calculadas de 58,8% para a escala de estratificação de risco Hema-Obs e de 38,7% para a escala de estratificação 
de risco de Sarig, correspondendo a uma diferença estatisticamente significativa (p = 0,0006 pelo teste de DeLong). Nas gestações 
acompanhadas no Centro Hospitalar São João EPE verificaram-se 91% de gestações bem-sucedidas e 9% de abortamentos; nas 
gestações acompanhadas por Sarig verificaram-se 82% de gestações bem-sucedidas e 18% de abortamentos.
Conclusões: Conclui-se que a escala de estratificação de risco Hema-Obs constitui um suporte eficaz para estratégias terapêuticas 
de acompanhamento clínico.
Palavras-chave: Estudo Comparativo; Gravidez; Israel; Medição de Risco; Portugal; Trombofilia.
ABSTRACT
Introduction: Pregnant women with thromboembolic diseases, previous thrombotic episodes or thrombophilia family history were su-
pervised in a multidisciplinary Obstetrics/Hematology consultation in Centro Hospitalar São João EPE, Porto, Portugal. For the evalu-
ation and medication of these women, a risk stratification scale was used. 
Purposes: The aim of this study was to validate a Risk Stratification Scale and thromboprophylaxis protocol by means of comparing it 
with a similar scale, developed and published by Sarig.
Material and Methods: We have compared: The distribution, by risk groups, obtained through the application of the two scales on 
pregnant women followed at Centro Hospitalar São João, Porto, Portugal, consultation; the sensibility and specificity for each one of 
the scales (DeLong scale, applied to Receiver Operating Characteristic) curves; the outcomes in pregnancies followed in Hospital São 
João, Porto, Portugal
Results: According to our Hema-Obs risk stratification scale, 29% were allocated to low-risk, 47% to high-risk and 24% to very-high-risk 
groups. According to Galit Sarig risk stratification scale, 24% were considered low-risk, 53% moderate, 16% high-risk and 7% as very 
high-risk group. In our study we observed 9% of spontaneous abortions, in comparison with 18% in the Galit Sarig cohort. From the 
application of Receiver Operating Characteristic curve to both risk stratification scales, the results of the calculated areas were 58,8% 
to our Hema-Obs risk stratification scale and 38,7% to Galit Sarig risk stratification scale, with a Delong test significancie of p = 0.0006.
Conclusions: We concluded that Hema-Obs risk stratification scale is an effective support for clinical monitoring of therapeutic strate-
gies.
Keywords: Comparative Study; Israel; Portugal; Pregnancy; Risk Assessment comparative study; Thrombophilia.
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INTRODUCTION
 Pregnancy represents a physiological hypercoagulabil-
ity state related to the increased concentration of some co-
agulation factors accompanied by a reduced concentration 
of inhibitors, mainly protein S.1,2 In addition there is reduced 
fibrinolytic activity associated to the reduction of plasmino-
gen activator tissue levels and an increase in plasminogen 
activator inhibitor (PAI) levels.2,5-7
 Venous stasis is also increased starting from the initial 
stage of pregnancy. This is due to the action of progesterone 
on the venous wall and mechanical factors opposing venous 
return, in turn due to the growth of the pregnant uterus.3
 Pregnancy is therefore associated to an increased risk 
of venous and pulmonary thromboembolic disease is the 
major direct cause of maternal mortality.9-11 Nevertheless, 
the absolute risk remains low, with an incidence of 1 per 
1,000 pregnancies.1,6,7,9-12
 Several studies also suggest the presence of an 
association between the risk for venous thromboembolism 
and gestational complications namely preeclampsia, 
recurrent pregnancy loss, intrauterine growth restriction 
(IUGR) and placental perfusion defects.4,13
 As such, the presence of risk factors for venous 
thromboembolism (VTE) is a strong clinical indication for 
prophylactic anticoagulation with low-molecular weight 
heparin (LMWH) in pregnancy,9-14 efficient and safe for the 
foetus (as these do not cross the placental barrier) and 
for the mother, with minimal haemorrhagic and  heparin-
induced thrombocytopenia (HIT) and very low risk of an 
osteoporotic fracture (0.04%). The anticoagulant effect 
of LMWH is predictable and reliable with exceptional 
requirements for laboratory monitoring.3,10
 The multidisciplinary Haematology-Obstetrics 
Outpatient Department at the Centro Hospitalar São João 
EPE (CHSJ) is a referral centre for pregnant mothers 
with haematological and thromboembolic pathology. 
Sixty percent of patients correspond to women with 
haematological disorders related to coagulation factor 
deficiency. The remaining 40% correspond to women with 
thrombophilia, prior thrombotic episodes (whether or not 
associated to previous pregnancies and/or with a family 
history of thrombophilia) further to clinical research due to 
previous obstetric adverse outcome events. These women 
were subject to risk stratification, using the systematic 
application of a Risk Stratification Scale (Hema-Obs) during 
the medical examination, in order to determine treatment 
and prevention of maternal thrombotic episodes and/
or maternal or foetal adverse outcomes associated to a 
vascular cause of placental insufficiency.
OBJECTIVES
 Our study aimed to assess the efficacy of the risk-
stratification scale applied at the Haematology-Obstetrics 
Outpatient Department - (Hema-Obs) in order to obtain a 
sustained improvement of healthcare quality provided to 
pregnant mothers with the risk for VTE. In more detail, we 
aimed to assess the level of adequacy of this diagnostic 
tool through relating the classification of the risk groups with 
the therapeutic strategies, the final results of the obstetric 
follow-up and a comparative analysis with the results of the 
application of another risk-stratification scale (Galit Sarig, 
2009).1
MATERIAL AND METHODS
 A three-stage methodology was used: I) both the Hema-
Obs scale (Table 1) and the scale by Galit Sarig et al. 
(2009)1 were simultaneously applied to 250 consecutive 
pregnant mothers observed at the Haematology-Obstetrics 
Outpatient Department over a 10-year period (2000-2010). A 
comparative analysis of risk group distribution was obtained 
for each scale; II) the Receiver Operating Characteristic 
(ROC) curve15 and DeLong’s test15 were applied to both 
scales, III) pregnancy outcomes were compared: a) CHSJ 
(250 pregnancies), Porto, Portugal vs. b) Galit Sarig (90 
pregnancies), at the Rambam Health Care Campus, Israel.1
RESULTS
I) Risk-stratification scale application to 250 consecutive 
pregnant mothers observed at the Haematology-
Obstetrics Outpatient Department of CHSJ
 In the scale proposed by Galit Sarig (2009),1 the risk 
factors were grouped into four categories: obstetric history, 
type of thrombophilia, previous thromboembolic episode and 
family history of thromboembolism. A score corresponded 
to each risk factor and the sum generated a final score and 
one from four possible risk levels was assigned to each 
pregnant mother: low, intermediate, high and extremely 
high risk. There is no specific reference to therapy on the 
Galit Sarig scale and no reference to dosage optimization 
for each risk group.1
 The foetal risk and whether or not the pregnant mother 
completed any previous anticoagulant therapy, beyond 
clinical and laboratorial factors, were also included in the 
Hema-Obs scale, allowing for the definition of three risk 
groups, with well-defined therapeutic approaches: a) 
maternal high risk: postpartum (first six weeks upon delivery) 
LMWH in a prophylactic dose; b) foetal and maternal high 
risk: pregnancy and postpartum LMWH prophylaxis; c) 
foetal and maternal extremely high risk: pregnancy and 
postpartum LMWH in therapeutic dose.
 The results of risk stratification upon Hema-Obs scale 
application to 250 pregnant mothers showed that 24% 
(61 pregnancies) were considered as foetal and maternal 
extremely high risk; 47% (117 pregnancies) as foetal and 
maternal high risk and 29% (72 pregnancies) as maternal 
high risk (Fig.1).
 The application of the Galit Sarig scale showed 7% (18 
pregnancies) extremely high risk pregnancies, 16% (40 
pregnancies) high risk; 53% (131 pregnancies) intermediate 
risk and 24% (61 patients) low risk, (Fig. 2).
 The comparative assessment of the results showed a 
higher prevalence of pregnancies within maternal and foetal 
high risk group when the Hema-Obs scale was applied 
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Table 1 – Hema – Obs scale [J. Aguiar Andrade (JAA) & Mariana Guimarães (MG)] 
Classification of risk  Risk factors
Maternal and Foetal 
extremely high risk 
pregnancy
Any of the following:
  Anticoagulant therapy
  Antithrombin III < 0.70 
  Thromboembolic episode in current or in previous pregnancy
  Antiphospholipid syndrome (APS)
  Homozygosity / double heterozygosity for factor V Leiden and/or PT G20210A mutations
Therapy Enoxaparin 1 mg/Kg 12/12h sc injection or dalteparin 100 IU/ kg 12/12h sc or tinzaparin: 175 IU/ kg 1x day sc 
in pregnancy and postpartum
Maternal and foetal 
high risk pregnancy
Any of the following:
  Previous thromboembolic event outside pregnancy, without any thrombotic risk factor * and with Protein 
    C < 0.75 or Protein S < 0.30 or increased activated protein C resistance
  Obstetric risk history**
  Recurrent miscarriage before the 10th week of gestation (≥ 2 consecutive; ≥ 3 interspersed)
  ≥ 1 foetal death with normal morphology by direct or ultrasound examination
  Isolated APS laboratorial criteria (with no clinical criteria or in primiparous mothers)
  Thromboembolic direct family history
  Heterozygosity for the factor V Leiden or PT G20210A mutations associated to Protein C < 0.75 or Protein 
    S < 0.30  or ≥ 3 thrombotic risk factors
Therapy Enoxaparin: 40 mg/ day sc or dalteparin: 5,000 IU/ day or 4,500 IU/ day sc in pregnancy and postpartum
Maternal high risk 
pregnancy
Any of the following:
  Thromboembolic episode outside pregnancy with maintained risk factor
  Thromboembolic episode outside pregnancy with 0.30 < Protein S <0.50 
  1-2 thrombotic risk factors with 0.30 < Protein S < 0.50 
  Simple heterozygosity for factor V Leiden or PT G20210A mutations
Therapy Enoxaparin: 40 mg/ day sc or dalteparin: 5,000 IU/ day or tinzaparin 4,500 IU/ day sc in postpartum
* Thrombotic risk factors: obesity (BMI > 30, hyperlipidaemia, extensive varicose veins, age > 35 years; smoking habit, multiparity > 3)
** Obstetric risk history: post 20th week foetal death; severe pre-eclampsia; HELLP syndrome; abruption placenta; intrauterine growth restriction (IUGR) with foetal biometry below 5th 
percentile)
 
Figure 1 – Risk stratification according to the Hema–Obs scale
 
Figure 2 – Risk stratification according to the Galit Sarig scale
whilst the Galit Sarig scale showed a higher prevalence of 
intermediate risk pregnancies. 
 In addition, a smaller percentage (7% vs. 24%) of 
extremely high risk pregnancies was found with the Galit 
Sarig scale (corresponding to the group of pregnancies with 
maternal and foetal extremely high risk in Hema-Obs scale). 
A more detailed comparison between extremely high risk 
pregnancies showed that 7% of the pregnancies submitted 
to Galit Sarig scale have a similar ranking to the Hema-Obs 
scale. The latter scale added 43 pregnancies (17%) to this 
group of pregnancies, almost all associated to foetal risks.
 In short, there is a risk of overvaluation with the 
application of the Hema-Obs scale, when the risk is ranked 
in high and extremely high levels, while in the Galit Sarig 
Hema-Obs scale Galit Sarig scale
Maternal high risk Low
Maternal and foetal 
high risk
Intermediate
Maternal and foetal 
extremely high risk
High
Extremely high
24%
15%
7%
29% 24%
47% 53%
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Figure 3 – ROC curve applied to Hema-Obs scale Figure 4 – ROC curve applied to Galit Sarig scale 
Figure 5 – Pregnancy outcome (pregnant mothers observed at the 
CHSJ)
Figure 6 – Pregnancy outcome (pregnant mothers observed at the 
Rambam Health Care Campus, Israel)
scale, the risk is somewhat more undervalued.
II) ROC curve and DeLong’s test application to the 
Hema-Obs and Galit Sarig scales
 When the ROC curve was applied to the Hema-Obs 
scale (Fig. 3) the AUC was 58.8%, compared to the ROC 
curve applied to the Galit Sarig scale (Fig. 4), where the 
AUC was 38.7%. There was a highly significant difference 
between both methods (p = 0.0006175, according to the 
DeLong’s test).
 ROC curves were applied to the same population (250 
pregnant mothers attended at the CHSJ). 
III) Outcome assessment of the attended pregnancies
 In our group of 250 pregnant mothers attended at 
the CHSJ, 91% (227 pregnant mothers) had successful 
pregnancies and 9% of miscarriages/foetal death (23 
pregnancies) occurred (Fig. 5).
 An 82% rate of successful pregnancies (74 pregnancies) 
and 18% miscarriages / foetal death (16 pregnancies) were 
found in the 90 pregnancies included in the study by Galit 
Sarig (Fig. 6).1 
DISCUSSION
 When compared to the Galit Sarig scale, the Hema-Obs 
scale showed an overvaluation of the risk as a significantly 
higher rate of extremely high risk pregnancies was found 
(24% vs. 7%).
 However, this situation is due to the fact that the risks 
associated to pregnancy – which are significant - were 
ignored in the Galit Sarig scale. Therefore, the therapeutic 
intervention associated to this assessment, milder and 
above all involving a lower number of pregnant mothers, 
seems to have had an impact on the miscarriage/foetal 
death rate, which doubled in the Galit Sarig scale (18%) 
when compared to the Hema-Obs scale (9%). 
 The logistic model of our study does not have enough 
discriminatory power to allow us to claim that the Hema-
Obs scale has higher adequacy to risk factors stratification 
in pregnant mothers with thromboembolic risk. The fact 
that this scale was applied to a higher number of pregnant 
mothers may have influenced the study results. 
 However, we may infer that had the Galit Sarig scale 
been applied to a group of pregnant mothers attended at the 
CHSJ, less women would have been treated. Conversely, 
had the Hema-Obs scale been applied to the group of 
pregnant mothers at the Rambam Health Care Campus, the 
treatment group would have increased.
CONCLUSION
 Our study allowed for the conclusion that the Hema-
Obs scale is an efficient support to therapeutic strategies, 
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Miscarriage / foetal death Miscarriage / foetal death
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improving the outcomes of gestations and in the end the 
quality of healthcare provided to pregnant mothers and 
newborns.
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